(EP3158995) 1. Composition comprising an effective amount of meglumine or a salt thereof for reducing or preventing the increase of triglyceride levels, or reversing a physiological condition associated with high triglyceride levels in a subject in need thereof. 2. Composition according to claim 1, wherein the composition further comprises an acceptable carrier. 3. Composition according to claim 2, wherein the acceptable carrier is at least one selected from the group consisting of a liquid or solid filler, sugar, starch, cellulose or derivative thereof, powdered tragacanth, malt, gelatin, talc, oil, glycol, polyol, ester, agar, buffering agent, alginic acid, pyrogen-free water, isotonic saline, isotonic agent, Ringer's solution, ethyl alcohol, phosphate buffer solution, diluent, granulating agent, lubricant, binder, disintegrating agent, wetting agent, emulsifier, coloring agent, release agent, coating agent, sweetening agent, flavoring agent, perfuming agent, preservative, antioxidant, plasticizer, gelling agent, thickener, hardener, setting agent, suspending agent, surfactant, humectant, stabilizer, coating, antibacterial agent, antifungal agent, absorption delaying agent and lecithin. 4. Composition according to any of the preceding claims, wherein the composition is formulated for inhalational, oral, rectal, vaginal, parenteral, topical, transdermal, pulmonary, intranasal, buccal, ophthalmic, intrathecal, parenteral, intravenous, or another route of administration. 5. Composition according to any of the preceding claims, wherein the composition is formulated for injection. 6. Composition according to any of the preceding claims, wherein the composition is formulated for administration at a frequency selected from the group consisting of once a day, twice a day, three times a day, four times a day, once a week, twice a week, three times a week, four times a week, once a month, twice a month, and any combinations thereof. 7. Composition according to any of the preceding claims, wherein the composition is formulated for administration at a dosage ranging from about 1 ng/kg/application to about 100 g/kg/application. 8. Composition according to any of the preceding claims, wherein the composition is formulated for administration at a dosage ranging from about 1 ng/kg/application to about 100 mg/kg/application. 9. Composition according to any of the preceding claims, wherein the composition is a controlled-release formulation. 10. Composition according to any of the preceding claims, wherein the composition is combined with a medication for treating symptoms of diabetes. 11. Composition according to any of the preceding claims, wherein the subject is a mammal. 12. Composition according to any of the preceding claims, wherein the subject is a human.
最新评论
暂无评论。